AU2002229536A1 - Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-Dihydroxy-pregna-1,4-dien-3,20-dion or its21-isobutyrat by transketalisation - Google Patents

Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-Dihydroxy-pregna-1,4-dien-3,20-dion or its21-isobutyrat by transketalisation

Info

Publication number
AU2002229536A1
AU2002229536A1 AU2002229536A AU2002229536A AU2002229536A1 AU 2002229536 A1 AU2002229536 A1 AU 2002229536A1 AU 2002229536 A AU2002229536 A AU 2002229536A AU 2002229536 A AU2002229536 A AU 2002229536A AU 2002229536 A1 AU2002229536 A1 AU 2002229536A1
Authority
AU
Australia
Prior art keywords
formula
hydrogen
dihydroxy
pregna
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002229536A
Other versions
AU2002229536B2 (en
Inventor
Beate Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covis Pharma GmbH
Original Assignee
Covis Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covis Pharma GmbH filed Critical Covis Pharma GmbH
Publication of AU2002229536A1 publication Critical patent/AU2002229536A1/en
Application granted granted Critical
Publication of AU2002229536B2 publication Critical patent/AU2002229536B2/en
Assigned to NYCOMED GMBH reassignment NYCOMED GMBH Request for Assignment Assignors: ALTANA PHARMA AG
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: NYCOMED GMBH
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: TAKEDA GMBH
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: TAKEDA GMBH
Assigned to COVIS PHARMA B.V. reassignment COVIS PHARMA B.V. Request for Assignment Assignors: ASTRAZENECA AB
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Description

PROCESS FOR THE PRODUCTION OF 16 , 17- * ( CYCLOHEXY ETHYLEN) BIS (OXY) ! -11 , 21-DIHYDROXY-PREGNA-1 , 4-DIEN-3 , 20-DION OR ITS 21-ISOBUTYRAT BY TRANSKETA ISATION
Technical field
The invention relates to a novel process for the preparation of a known glucocorticoid, which is used in the pharmaceutical industry for the production of medicaments.
Prior art
The international patent application WO 9422899 describes novel prednisolone derivatives and a process for their preparation. In this process, 16-hydroxyprednisolone is reacted with cyclohexanealdehyde. German patent application DE 41 29 535 discloses novel glucocorticoids and a process for their preparation. The process comprises reacting pregna-1,4-diene-3,20-d.one-16, 17-dihydroxy compounds, in the form of their 16,17-diester derivatives, with aldehydes (e.g. with cyclohexanealdehyde) to give the desired final products.
Description of the invention
The invention relates to a process for the preparation of the compounds of the formula 1 ,
in which
R is hydrogen (H) or isobutyryl [CO-CH(CH3)2], in predominantly epimerically pure form.
It has now been found that the compounds of the formula 1 are obtained in a simple manner in good yield and surprisingly high epimeric purity when, rather than the 16,17-dihydroxy compound or the 16,17-diester, the corresponding 16,17-ketal, in particular the 16,17-acetonide derivative, is used as a starting material. The invention thus relates to a process for the preparation of the compounds of the formula 1 in predominantly epimerically pure form, which comprises reacting compounds of the formula 2,
in which
R is hydrogen (H) or isobutyryl [CO-CH(CH3)2],
R1 is 1-4C-alkyl and
R2 is1-4C-alkyl, with cyclohexanealdehyde.
Preferably, the process is carried out using those compounds of the formula 2 in which R1 and R2 are in each case methyl (CH3).
The reaction is carried out in suitable solvents such as, for example, ethers, e.g. dioxane, diisopropyl ether, esters, e.g. ethyl acetate, halogenated hydrocarbons, e.g. methylene chloride, chloroform, nitrated hydrocarbons, e.g. nitromethane, 2-nitropropane or preferably 1-nitropropane, or without solvents, with addition of catalytic or else relatively large amounts of acid, such as mineral acids, e.g. tetrafluoroboric acid or in particular perchloric acid, or sulfonic acids, in particular methanesulfonic acid, at temperatures of advantageously 0°C to 60°C.
The reaction of the 16-hydroxyprednisolone ketal of the formula 2 with cyclohexanealdehyde normally yields an epimer mixture. Surprisingly, the reaction, however, is controlled according to the invention by means of suitable reaction conditions such that the R-epimer desired and indicated in formula 1 results. According to the invention, "in predominantly epimerically pure form" thus means that the R- epimer (based on the absolute configuration at C-22) in the compound 1 where R = hydrogen (H) results to at least 90%, preferably at least 95%, in particular at least 97%, based on the total yield.
For the predominant preparation of the R-epimer, the following conditions, for example, are preferred: as solvents, halogenated hydrocarbons (such as methylene chloride or chloroform) or nitrated hydrocarbons (such as nitromethane, 2-nitropropane or preferably 1-nitropropane) and, as a catalyst, methanesulfonic acid (at temperatures from 10°C to 40°C) or 35-70% strength, in particular 60-70% strength, perchloric acid (at temperatures from 0°C to 40°C, preferably 15°C to 30°C, in particular 20°C to 25°C).
If the R-epimer is desired in purer form than is achievable on account of the reaction conditions, suitable separation and purification steps - such as, for example, preparative HPLC, or fractional crystallization such as described in international patent application WO 9809982 - may follow the reaction.
The following example serves to illustrate the invention in greater detail:
Example
Iβ.^-KCycIohexylmethyleneJbistoxyJJ-H^I-dihydroxypregna-l^-diene-SjZO-dionelllβ.ieαlR)]
20 g of desonide are suspended in 70 ml of 1-nitropropane and treated slowly with ice-cooling with 12.6 ml of 70% strength perchloric acid and 6.6 g of cyclohexanealdehyde. The reaction mixture is stirred overnight at room temperature and then filtered. The filter cake is dissolved in 90 ml of DMF and the solution is added dropwise with stirring to sodium hydrogencarbonate solution. The precipitate is filtered off with suction, washed with water and dried. 19 g of the title compound having an R-l S-epimer ratio of 97.8 / 2.2 are obtained.

Claims (9)

Patent claims
1. A process for the preparation of the compounds of the formula 1 ,
in which
R is hydrogen (H) or isobutyryl [CO-CH(CH3)2], in predominantly epimerically pure form,
which comprises reacting compounds of the formula 2,
in which
R is hydrogen (H) or isobutyryl [CO-CH(CH3)2],
R1 is 1-4C-alkyl and
R2 is1-4C-alkyl, with cyclohexanealdehyde.
2. The process as claimed in claim 1 , where R is hydrogen (H).
3. The process as claimed in claim 1 , where R is isobutyryl [CO-CH(CH3)2].
4. The process as claimed in claim 1 , where R1 and R2 are in each case methyl (CH3).
5. The process as claimed in claim 1 , wherein a halogenated or nitrated hydrocarbon is used as a solvent.
6. The process as claimed in claim 1 , wherein methanesulfonic acid is used as a catalyst.
7. The process as claimed in claim 1 , wherein perchloric acid is used as a catalyst.
8. The process as claimed in claim 1 , wherein the reaction is carried out at temperatures between 0°C and 40°C.
9. The process as claimed in claim 1 for the preparation of the compound of the formula 1 , in which R is hydrogen (H), in over 95 % epimerically pure form, wherein compounds of the formula 2, in which R is hydrogen (H), R1 is methyl (CH3) and R2 is methyl (CH3), are reacted with cyclohexanealdehyde using perchloric acid as a catalyst at temperatures between 0°C and 40°C.
AU2002229536A 2000-11-10 2001-11-06 Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-Dihydroxy-pregna-1,4-dien-3,20-dion or its21-isobutyrat by transketalisation Expired AU2002229536B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00124626.3 2000-11-10

Publications (2)

Publication Number Publication Date
AU2002229536A1 true AU2002229536A1 (en) 2002-07-25
AU2002229536B2 AU2002229536B2 (en) 2007-04-19

Family

ID=

Similar Documents

Publication Publication Date Title
AU2007298770B2 (en) Processes for the preparation of ciclesonide and its crystal form
CA2430196C (en) Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-dihydroxy-pregna-1,4-dien-3,20-dion or its 21-isobutyrat by transketalisation
US20070117974A1 (en) One-pot processes for preparing prednisolone derivatives
FI90345B (en) Process for controlling the epimer distribution in the preparation of 16,17-acetals of pregnane derivatives
AU4456797A (en) Process for R-epimer enrichment of 16,17-acetal derivatives of 21-acyloxy pregan-1,4-dien-11.beta,16.alpha.,17.alpha.- triol-3,20-dione derivatives
CN109206441B (en) Purification method of everolimus
AU2002229536B2 (en) Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-Dihydroxy-pregna-1,4-dien-3,20-dion or its21-isobutyrat by transketalisation
AU2002229536A1 (en) Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-Dihydroxy-pregna-1,4-dien-3,20-dion or its21-isobutyrat by transketalisation
DE10055820C1 (en) Preparation of 16,17-cyclohexylmethylene-dioxy-pregnadiene derivative, useful as glucocorticoid, by reacting 16,17-ketal with cyclohexylaldehyde to give high epimeric purity
JPH023797B2 (en)
EP0994119B1 (en) Stereoselective process for the preparation of the 22R epimer of budesonide
CA2568510C (en) One-pot processes for preparing prednisolone derivatives
JPH0565294A (en) 20-isocyano-20-sulfonyl-delta 16-steroid and process for producing same
HU185797B (en) Process for producing 3-oxo-17-alpha-ethinyl-17beta-trifluoroacetoxy-gonane derivatives